Dr. Lutzker on OX40 Agonist in Patients With Refractory Solid Tumors
Stuart Lutzker, MD, PhD, vice president of BioOncology Exploratory Clinical Development, Genentech, discusses results of the first-in-human study of OX40 agonist in patients with refractory solid tumors.
Nivolumab Plus Relatlimab Demonstrates Consistent Benefit for Patients with Advanced Melanoma
Dr Rini on Sustained Survival Outcomes After Completion of Pembrolizumab and Axitinib in ccRCC
Dr Tolaney on Final OS Data From the TROPiCS-02 Trial in HR+/HER2- Breast Cancer
BL-B01D1 Demonstrates Antitumor Activity in EGFR+ NSCLC and Other Solid Tumors
2 Clarke Drive Cranbury, NJ 08512